China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.
Zhou M, Chen X, Zhang H, Xia L, Tong X, Zou L, Hao R, Pan J, Zhao X, Chen D, Song Y, Qi Y, Tang L, Liu Z, Gao R, Shi Y, Yang Z.
Zhou M, et al. Among authors: chen d, chen x.
Cancer Commun (Lond). 2019 Jun 20;39(1):36. doi: 10.1186/s40880-019-0383-7.
Cancer Commun (Lond). 2019.
PMID: 31221221
Free PMC article.
Review.